Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ibrutinib Monotherapy in Early Stage High-Risk CLL/SLL
NCT03207555Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- May 2018
- Primary completion
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ibrutinib in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), sponsored by University of Texas MD Anderson Cancer Center. Primary endpoints: Complete Remission at 24 months and Partial Remission at 24 months. Started May 2018; status: completed.
02
Drugs
ibrutinib
03
Conditions
chronic lymphocytic leukemia (CLL)small lymphocytic lymphoma (SLL)
Beyond the preview
Go deeper on NCT03207555.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03207555.